Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

1.

Beyond BRAF in melanoma.

Daud A, Bastian BC.

Curr Top Microbiol Immunol. 2012;355:99-117. doi: 10.1007/82_2011_163. Review.

PMID:
21826607
[PubMed - indexed for MEDLINE]
2.

MEK and RAF inhibitors for BRAF-mutated cancers.

Belden S, Flaherty KT.

Expert Rev Mol Med. 2012 Oct 12;14:e17. doi: 10.1017/erm.2012.11. Review.

PMID:
23058743
[PubMed - indexed for MEDLINE]
3.

Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.

Smalley KS, Nathanson KL, Flaherty KT.

Cancer Res. 2009 Apr 15;69(8):3241-4. doi: 10.1158/0008-5472.CAN-08-4305. Epub 2009 Apr 7. Review.

PMID:
19351826
[PubMed - indexed for MEDLINE]
Free Article
4.

Therapeutic targets in melanoma: map kinase pathway.

Haluska FG, Ibrahim N.

Curr Oncol Rep. 2006 Sep;8(5):400-5. Review.

PMID:
16901402
[PubMed - indexed for MEDLINE]
5.

Novel inhibitors in the treatment of metastatic melanoma.

Kalinsky K, Haluska FG.

Expert Rev Anticancer Ther. 2007 May;7(5):715-24. Review.

PMID:
17492934
[PubMed - indexed for MEDLINE]
6.

Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.

Bradish JR, Montironi R, Lopez-Beltran A, Post KM, MacLennan GT, Cheng L.

Future Oncol. 2013 Feb;9(2):245-53. doi: 10.2217/fon.12.179. Review.

PMID:
23414474
[PubMed - indexed for MEDLINE]
7.

Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.

Pritchard AL, Hayward NK.

Clin Cancer Res. 2013 May 1;19(9):2301-9. doi: 10.1158/1078-0432.CCR-12-0383. Epub 2013 Feb 13. Review.

PMID:
23406774
[PubMed - indexed for MEDLINE]
Free Article
8.

BRAF inhibitors and melanoma.

Flaherty KT.

Cancer J. 2011 Nov-Dec;17(6):505-11. doi: 10.1097/PPO.0b013e31823e5357. Review.

PMID:
22157295
[PubMed - indexed for MEDLINE]
9.

MAP kinase signaling and inhibition in melanoma.

Sullivan RJ, Flaherty K.

Oncogene. 2013 May 9;32(19):2373-9. doi: 10.1038/onc.2012.345. Epub 2012 Sep 3. Review.

PMID:
22945644
[PubMed - indexed for MEDLINE]
10.

Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.

Sáez JM.

Anticancer Agents Med Chem. 2013 Mar;13(3):483-95. Review.

PMID:
22583421
[PubMed - indexed for MEDLINE]
11.

Biological challenges of BRAF inhibitor therapy.

Puzanov I, Burnett P, Flaherty KT.

Mol Oncol. 2011 Apr;5(2):116-23. doi: 10.1016/j.molonc.2011.01.005. Epub 2011 Feb 16. Review.

PMID:
21393075
[PubMed - indexed for MEDLINE]
Free Article
12.

BRAF as therapeutic target in melanoma.

Wellbrock C, Hurlstone A.

Biochem Pharmacol. 2010 Sep 1;80(5):561-7. doi: 10.1016/j.bcp.2010.03.019. Epub 2010 Mar 27. Review.

PMID:
20350535
[PubMed - indexed for MEDLINE]
13.

BRAF, a target in melanoma: implications for solid tumor drug development.

Flaherty KT, McArthur G.

Cancer. 2010 Nov 1;116(21):4902-13. doi: 10.1002/cncr.25261. Review.

PMID:
20629085
[PubMed - indexed for MEDLINE]
Free Article
14.

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?

Nissan MH, Solit DB.

Curr Oncol Rep. 2011 Dec;13(6):479-87. doi: 10.1007/s11912-011-0198-4. Review.

PMID:
21997758
[PubMed - indexed for MEDLINE]
15.

The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.

Haluska F, Pemberton T, Ibrahim N, Kalinsky K.

Semin Oncol. 2007 Dec;34(6):546-54. Review.

PMID:
18083378
[PubMed - indexed for MEDLINE]
16.

Molecularly targeted therapies for melanoma.

Liu LS, Colegio OR.

Int J Dermatol. 2013 May;52(5):523-30. doi: 10.1111/j.1365-4632.2012.05829.x. Review.

PMID:
23590367
[PubMed - indexed for MEDLINE]
17.

BRAF signaling and targeted therapies in melanoma.

Dhomen N, Marais R.

Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix. doi: 10.1016/j.hoc.2009.04.001. Review.

PMID:
19464601
[PubMed - indexed for MEDLINE]
18.

Therapeutic strategies for targeting BRAF in human cancer.

Pratilas CA, Solit DB.

Rev Recent Clin Trials. 2007 May;2(2):121-34. Review.

PMID:
18473997
[PubMed - indexed for MEDLINE]
19.

BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.

Sclafani F, Gullo G, Sheahan K, Crown J.

Crit Rev Oncol Hematol. 2013 Jul;87(1):55-68. doi: 10.1016/j.critrevonc.2012.11.003. Epub 2012 Dec 12. Review.

PMID:
23246082
[PubMed - indexed for MEDLINE]
20.

[The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].

Zafon C, Obiols G.

Endocrinol Nutr. 2009 Apr;56(4):176-86. doi: 10.1016/S1575-0922(09)70982-9. Epub 2009 Jun 11. Review. Spanish.

PMID:
19627734
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk